Creating sustainable access to life-saving medicines.
Aradigm is the first comprehensive cell & gene therapy carve-out.
We stand at a remarkable moment in science. Cell and gene therapies can treat diseases that were once thought to be untreatable, but they carry a steep price tag that threatens access. Our healthcare system simply isn’t built for delivering or paying for these kinds of medicines. Addressing this problem requires more than a simple fix, and that’s why we built Aradigm.
We have created a novel financial and delivery model that addresses the challenges facing every stakeholder — payers, providers, manufacturers, and most importantly, patients.
Pillars Of Impact
Patient Focus
Delivering quality outcomes and a concierge-level experience for every patient we serve
Sustainable Coverage
Ensuring eligible patients receive the therapies they need through reliable, equitable delivery
Affordable Access
Providing transparent, predictable CGT pricing to support sustainable access
Why Now?
CGT costs range from $1 - $4M+
$1–4M
Increasing approvals require improved infrastructure to ensure sustainable access for patients
10x more approvals within 3–5 years
Car-T episode costs vary by over 242% between providers, with similar outcomes
242% care pricing variation
Stakeholder Benefits Overview
Employers & Insurers
Bend the cost curve of high-cost therapeutics while elevating clinical quality and member support
Providers
Garner predictable volume, mitigate cashflow risk, and reduce complexity
Manufacturers
Unlock new avenues for access to your cutting-edge therapies in collaboration with providers, employers, and payers.
